Recent price performance and business snapshot

Illumina (ILMN) has seen pressure on its share price recently, with a 10% decline over the past day, 17% over the past week, and 15% over the past month. This has left the stock modestly lower over the past 3 months.

Despite these short term moves, the company reports annual revenue of US$4,343.0 and net income of US$850.0. Its results are supported by sequencing and array based products and services used across research, clinical, and commercial genomic applications.

Over longer horizons, Illumina’s total return is mixed, with a 7.8% gain over the past year contrasted with declines of 37% over 3 years and 75% over 5 years. These differing outcomes may influence how different shareholders view recent volatility.

Illumina’s recent 10.4% one day share price decline adds to weaker short term momentum, even though the 1 year total shareholder return of 7.8% still contrasts with the much deeper 3 and 5 year declines.

If Illumina’s genomics exposure has your attention, this can be a good moment to widen your watchlist with 26 healthcare AI stocks, a curated set of healthcare names linked to AI themes.

With Illumina trading at US$119.72 and internal estimates pointing to around a 20% intrinsic discount, plus a modest gap to analyst targets, should you consider potential upside here or assume the market is already pricing in future growth?

Most Popular Narrative: 11.9% Undervalued

Illumina’s most followed narrative pegs fair value at $135.94 per share, compared with the recent $119.72 close, and builds that gap on detailed long term forecasts.

Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling, along with tax headwinds turning into tailwinds, sets the stage for continued net margin and earnings growth over the next several years.

Curious what kind of revenue trajectory and profit margins are baked into that outcome, and how future P/E assumptions tie it all together? The narrative lays out a full earnings path, a target profitability range, and a valuation multiple that has to hold for the numbers to make sense, but the exact mix may surprise you.

Result: Fair Value of $135.94 (UNDERVALUED)

However, there is still clear downside risk if research funding stays tight or if China export and approval rules continue to weigh on instrument and consumables demand.

Build Your Own Illumina Narrative

If parts of this story do not quite fit your view, or you would rather lean on your own work, you can build a custom thesis in just a few minutes by starting with Do it your way.

A great starting point for your Illumina research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Illumina is on your radar, do not stop there. Broaden your opportunity set with focused stock ideas built from clear fundamentals and consistent criteria.

• Target potential value opportunities by scanning companies that our screener flags as 52 high quality undervalued stocks based on quality metrics and pricing signals.
• Strengthen your defense by reviewing businesses highlighted in our 82 resilient stocks with low risk scores that aim for resilient earnings and lower risk profiles.
• Spot under followed opportunities by searching the screener containing 24 high quality undiscovered gems that combine solid fundamentals with relatively limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.